- Home
- SHPH vs XXII Comparison
SHPH vs XXII Comparison
Compare SHPH & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHPH
- XXII
- Stock Information
- Founded
- SHPH 2012
- XXII 1998
- Country
- SHPH United States
- XXII United States
- Employees
- SHPH N/A
- XXII N/A
- Industry
- SHPH Biotechnology: Pharmaceutical Preparations
- XXII Medicinal Chemicals and Botanical Products
- Sector
- SHPH Health Care
- XXII Health Care
- Exchange
- SHPH Nasdaq
- XXII Nasdaq
- Market Cap
- SHPH 2.3M
- XXII 2.0M
- IPO Year
- SHPH 2022
- XXII N/A
- Fundamental
- Price
- SHPH $3.42
- XXII $2.43
- Analyst Decision
- SHPH
- XXII
- Analyst Count
- SHPH 0
- XXII 0
- Target Price
- SHPH N/A
- XXII N/A
- AVG Volume (30 Days)
- SHPH 157.2K
- XXII 2.7M
- Earning Date
- SHPH 09-03-2025
- XXII 08-14-2025
- Dividend Yield
- SHPH N/A
- XXII N/A
- EPS Growth
- SHPH N/A
- XXII N/A
- EPS
- SHPH N/A
- XXII N/A
- Revenue
- SHPH N/A
- XXII $23,869,000.00
- Revenue This Year
- SHPH N/A
- XXII $22.41
- Revenue Next Year
- SHPH N/A
- XXII $76.35
- P/E Ratio
- SHPH N/A
- XXII N/A
- Revenue Growth
- SHPH N/A
- XXII N/A
- 52 Week Low
- SHPH $3.00
- XXII $2.18
- 52 Week High
- SHPH $82.50
- XXII $2,328.75
- Technical
- Relative Strength Index (RSI)
- SHPH 39.42
- XXII 20.79
- Support Level
- SHPH $3.33
- XXII $2.18
- Resistance Level
- SHPH $3.83
- XXII $2.66
- Average True Range (ATR)
- SHPH 0.23
- XXII 0.31
- MACD
- SHPH -0.02
- XXII 0.33
- Stochastic Oscillator
- SHPH 10.78
- XXII 14.24
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.